PCMA said the changes wouldn’t be as disruptive as others argued, and highlighted several classes of drugs
Pharmaceutical companies gave at least $116 million to patient advocacy groups in a single year
Mark Merritt said “we always support, as an industry, patients paying lower price at the counter…it’s an outlier practice.”
Greater competition is the answer, Mr. Merritt said, and he praised recent efforts by the Food and Drug Administration
JC Scott (00:08): Welcome to the Pharmacy Benefit, a podcast where we talk about issues impacting patients, consumers, and affordable access to prescription drugs and better healthcare through the work being done by pharmacy benefit managers or PBMs. I’m
HEALTH EQUITY HEALTH EQUITY For America’s pharmacy benefit companies, our mission is simple: increase affordable access to prescription drugs for everyone. We believe care should be patient-focused, equitable, and affordable. LEARN MORE UNLOCKING AN AFFORDABLE FUTURE UNLOCKING AN AFFORDABLE FUTURE
Given this growing challenge, pharmacy benefit managers (PBMs) have never been more essential. For both public programs and private insurance, PBMs are actively engaged in keeping prescription drug costs down and making medications more affordable for individual patients.
©2024 PCMA. All Rights Reserved.
